secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seer, Inc. (SEER)
CIK:        0001726445
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-131802
Event type: litigation
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTAB upholds 23 claims of Seer's particle proteomics patent in Bruker challenge
-------------------------------------------------------------------------------

- PTAB Final Written Decision on March 23, 2026, upholds five challenged and 18 unchallenged claims of U.S. Patent No. 11,435,360.
- Patent covers protein enrichment using engineered nano- and microparticles, core to Seer's Proteograph platform.
- Petitioners PreOmics GmbH and Biognosys AG (Bruker subsidiaries) failed to show unpatentability of claims 2,3,7,23,24.
- Six claims (1,4,6,22,24,25) were found unpatentable; appeal deadline is May 25, 2026.
- '360 patent is owned by Brigham and Women's Hospital and exclusively licensed to Seer; CEO vows continued IP defense.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726445/000119312526131802/0001193125-26-131802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726445/000119312526131802/ck0001726445-20260323.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-131802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer